Journal of General Internal Medicine

, Volume 13, Issue 9, pp 586–593 | Cite as

HIV/AIDS patients’ perspectives on adhering to regimens containing protease inhibitors

  • Valerie E. Stone
  • Jennifer Clarke
  • Joan Lovell
  • Kathleen A. Steger
  • Lisa R. Hirschhorn
  • Stephen Boswell
  • Alicia D. Monroe
  • Michael D. Stein
  • Tamra J. Tyree
  • Kenneth H. Mayer
Original Articles

Abstract

OBJECTIVE: To gather qualitative data regarding HIV/AIDS patients’ perspectives about HIV-1 protease inhibitors (PIs), and about their experiences taking and adhering to regimens containing PIs.

DESIGN: Six focus groups of persons under care for HIV were conducted between September and November 1996 regarding participants’ knowledge, awareness, experiences when taking, and adherence to antiretroviral regimens containing PIs. An identical discussion guide was used to facilitate all six groups. Focus group proceedings were audiotaped, transcribed, coded for themes, and analyzed qualitatively.

SETTING: HIV/AIDS practices of three teaching hospitals and two community health centers.

PATIENTS/PARTICIPANTS: Fifty-six patients with HIV disease: 28 men and 28 women.

MEASUREMENTS AND MAIN RESULTS: Knowledge and positive impressions of PIs were prevalent among this diverse group of persons with HIV, and did not differ by race/ethnicity or gender. Most knew that these were new, potent medications for treating HIV/AIDS. Networks of persons with HIV and medical providers were the most important information sources. Those taking PIs were aware that adherence to the regimen is important, and most were using special strategies to maximize their own adherence, but expressed considerable frustration about the central role these medication regimens had assumed in their life. A subset who did not believe they would adhere to these regimens had declined treatment with them. Motivating factors for taking and adhering to these complex regimens were improving CD4 counts and viral loads and the patient-provider relationship.

CONCLUSIONS: Among those with HIV/AIDS, awareness of PIs and their effectiveness is substantial, owing to the impact of informal networks and medical providers. This early positive “reputation” of PIs may enhance motivation for adherence. Those who are taking PIs invest substantial effort adhering to these complex regimens, but resent the need to make medications the focus of their lives.

Key words

HIV/AIDS adherence compliance protease inhibitors antiretroviral therapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fauci AS. AIDS in 1996: much accomplished, much to do. JAMA. 1996;276:155–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Steinbrook R. Battling HIV on many fronts. N Engl J Med. 1997;337:779–81.PubMedCrossRefGoogle Scholar
  3. 3.
    Flexner C. HIV-1 protease inhibitors. N Engl J Med. 1998;338:1281–92.PubMedCrossRefGoogle Scholar
  4. 4.
    Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society—USA Panel. JAMA. 1997;277:1962–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. N Engl J Med. 1997;336:1531–2.PubMedCrossRefGoogle Scholar
  6. 6.
    Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–60.PubMedCrossRefGoogle Scholar
  7. 7.
    Centers for Disease Control and Prevention. Update: trends in AIDS incidence—United States, 1996. MMWR. 1997;46:861–7.Google Scholar
  8. 8.
    Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with HIV infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with HIV infection and CD4 cell counts of 200/mm3 or less. N Engl J Med. 1997;337:725–33.PubMedCrossRefGoogle Scholar
  10. 10.
    Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Draft document. Washington, DC: Department of Health and Human Services; June 19, 1997.Google Scholar
  11. 11.
    Report of the NIH Panel to Define Principles of HIV Infection. Draft document. Bethesda, Md: National Institutes of Health; June 19, 1997.Google Scholar
  12. 12.
    Bartlett JG. Protease inhibitors for HIV infection. Ann Intern Med. 1996;124:1086–8.PubMedGoogle Scholar
  13. 13.
    Bangsberg D, Tulsky JP, Hecht FM, Moss AR. Protease inhibitors in the homeless. JAMA. 1997;278:63–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 1995;374:569–71.PubMedCrossRefGoogle Scholar
  15. 15.
    Jacobsen H, Hanggi M, Ott M, et al. In vivo resistance to an HIV-1 protease inhibitor: mutations, kinetics and frequencies. J Infect Dis. 1996;173:1379–87.PubMedGoogle Scholar
  16. 16.
    Vanhove G, Shapiro J, Winters M, Merigan T, Blaschke T. Patient compliance and drug failure in protease inhibitor monotherapy. JAMA. 1997;276:1955–6.CrossRefGoogle Scholar
  17. 17.
    Meichenbaum D, Turk DC. Facilitating Treatment Adherence: A Practitioner’s Guidebook. New York, NY: Plenum Press; 1987:20.Google Scholar
  18. 18.
    Samet JH, Libman H, Steger KA, et al. Compliance with zidovudine therapy in patients infected with HIV-1: a cross-sectional study in a municipal hospital clinic. Am J Med. 1992;92:495–502.PubMedCrossRefGoogle Scholar
  19. 19.
    Smith MY, Rapkin BD, Morrison A, Kammerman S. Zidovudine adherence in persons with AIDS: the relation of patient beliefs about medication to self-termination of therapy. J Gen Intern Med. 1997;12:216–23.PubMedGoogle Scholar
  20. 20.
    Mostashari F, Blankenship K, Altice FL. “Trust” and HIV medication use among HIV+ inmates in Connecticut. Presented at the XIth International Conference on AIDS. Vancouver, BC, Canada, July 1996. Abstract Th.D.5189.Google Scholar
  21. 21.
    Shapiro J, Wolfe H, Sharp V. Patient attitudes toward zidovudine treatment as a function of behavioral, social, and demographic characteristics. Presented at the XIth International Conference on AIDS. Vancouver, BC, Canada, July 1996. Abstract Th.D.5188.Google Scholar
  22. 22.
    Samuels JE, Hendrix J, Hilton M, et al. Zidovudine therapy in an inner city population. J AIDS. 1990;3:877–83.Google Scholar
  23. 23.
    Singh N, Squier C, Sivek C, Wagener M, Hong Nguyen M, Yu VL. Determinants of compliance with antiretroviral therapy in patients with HIV. AIDS Care. 1996;8:261–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Muma RD, Ross MW, Parcel GS, Pollard RB. Zidovudine adherence among individuals with HIV infection. AIDS Care. 1995;7: 439–47.PubMedCrossRefGoogle Scholar
  25. 25.
    Broers B, Morabia A, Hirschel B. A cohort study of drug users compliance with zidovudine treatment. Arch Intern Med. 1994;154:1121–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Carpenter CCJ, Fischl MA, Hammer SM, et al. for the International AIDS Society—USA. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. JAMA. 1996;276:146–54.PubMedCrossRefGoogle Scholar
  27. 27.
    Morgan DL. Focus Groups as Qualitative Research. Beverly Hills, Calif: Sage Publications; 1988:53–70.Google Scholar
  28. 28.
    Glaser BG. Theoretical Sensitivity: Advances in the Methodology of Grounded Theory. Mills Valley, Calif: The Sociology Press; 1978.Google Scholar
  29. 29.
    Mullins PD, Reynolds R. The potential of grounded theory for health education research: linking theory and practice. Health Educ Monthly. 1978;6:280.Google Scholar
  30. 30.
    Centers for Disease Control and Prevention. HIV/AIDS Surveill Rep. 1996;8(2):1–22.Google Scholar
  31. 31.
    Mostashari F, Riley E, Selwyn PL, Altice FL. Acceptance and adherence with antiretroviral therapy among HIV-infected women in a correctional facility. J AIDS. 1998;18. In press.Google Scholar
  32. 32.
    Mays N, Pope C. Qualitative research: rigour and qualitative research. BMJ. 1995;311:109–12.PubMedGoogle Scholar
  33. 33.
    Kitzinger J. Qualitative research: introducing focus groups. BMJ. 1995;311:299–302.PubMedGoogle Scholar

Copyright information

© Society of General Internal Medicine 1998

Authors and Affiliations

  • Valerie E. Stone
    • 1
    • 3
    • 7
  • Jennifer Clarke
    • 6
    • 7
  • Joan Lovell
    • 4
  • Kathleen A. Steger
    • 8
  • Lisa R. Hirschhorn
    • 9
  • Stephen Boswell
    • 10
  • Alicia D. Monroe
    • 5
  • Michael D. Stein
    • 6
    • 7
  • Tamra J. Tyree
    • 1
  • Kenneth H. Mayer
    • 2
    • 3
    • 7
  1. 1.Received from the Divisions of General Internal MedicineMemorial Hospital of Rhode IslandPawtucket
  2. 2.Infectious DiseasesMemorial Hospital of Rhode IslandPawtucket
  3. 3.Department of MedicineMemorial Hospital of Rhode IslandPawtucket
  4. 4.Center for Primary Care and PreventionMemorial Hospital of Rhode IslandPawtucket
  5. 5.Department of Family MedicineMemorial Hospital of Rhode IslandPawtucket
  6. 6.Division of General Internal MedicineRhode Island HospitalProvidence
  7. 7.Department of MedicineBrown University School of MedicineProvidence
  8. 8.the Clinical AIDS Program, Department of MedicineBoston University School of MedicineUSA
  9. 9.Dimock Community Health CenterBoston
  10. 10.Fenway Community Health CenterBoston
  11. 11.Division of General Internal Medicine, Department of Medicine, Memorial Hospital of Rhode IslandBrown University School of MedicinePawtucket

Personalised recommendations